regorafenib,nivolumab
bms,bayer
['nivo', 'nivolumab', 'regorafenib']
 presenting the interim analysis of the #going trial of #regorafenib plus #nivolumab in #hcc at #uegweek. early morning session on #immunotherapy for hcc chaired by #livercancerawarenessmonth 
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma